The Serotonin Syndrome: Implicated Drugs, Pathophysiology and Management

Drug Safety

Volumn 13, Issue 2, 1995, Pages 94-104

  Sporer, Karl A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CYPROHEPTADINE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR; FENTANYL; FLUOXETINE; IPRONIAZID; LEVODOPA; LITHIUM; METHYSERGIDE; MONOAMINE OXIDASE INHIBITOR; PENTAZOCINE; PETHIDINE; PHENELZINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

ATAXIA; CENTRAL NERVOUS SYSTEM; CONFUSION; COOLING; DIAPHORESIS; DIARRHEA; DRUG FATALITY; DRUG TOXICITY; DRUG WITHDRAWAL; FEVER; HUMAN; HYPERREFLEXIA; HYPERTHERMIA; MYOCLONUS; NONHUMAN; PARALYSIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SHIVERING;

ANIMAL; DRUG INTERACTIONS; HUMAN; SEROTONIN AGENTS; SYNDROME;

EID: 0029103428     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199513020-00004     Document Type: Review

References (127)

1. International union of pharmacology classification or receptors for 5-hydroxytryptamine (serotonin)
2. The serotonin syndrome
3. Serotonin syndrome versus neuroleptic malignant syndrome a cause of death
4. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings
5. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses
6. Potentiation of pethidine
7. Pethidine and phenelzine
8. Possible lethal reaction between nardil and dextromethorphan
9. Toxic reaction to the combination of monoamine oxidase inhibitors and tryptophan
10. The hazards of use of monoamine oxidase inhibitors in disturbed adolescents
11. Side effects of phenelzine
12. Dangers of a too rapid substitution of imipramine for an inhibitor of monoamine oxidase and of the nialamide-ioniazid-barbiturate combination at high doses in psychiatric therapy
13. La prescription des psychotropes en pratique courante
14. Zur incompatibilitat zwischen monoamino-oxidase-hemmern and imipramine
15. Drug interaction with clomipramine (Anafranil)
16. Fluoxetine-monoamine oxidase inhibitor interaction
17. Imipramine-tranylcypromine incompatibility
18. Neuroleptic malignant syndrome without neuroleptics
19. Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome
20. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction
21. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction
22. Fluoxetine and the serotonin syndrome
23. Alarming reaction to pethidine in patients on phenelzine
24. Sertraline intoxication in a child
25. Life threatening interaction between phenelzine and L-tryptophan
26. The serotonin syndrome
27. Serotonin syndrome caused by a moclobemide-clomipramine interaction
28. Atropine-like poisoning due to tranquillizing agents
29. On the clinical course and therapy of pathological conditions caused by incompatible antidepressants
30. Motor effects of serotonin in the central nervous system
31. Serotonin toxicity: a comprehensive review for emergency medicine
32. Molecular basis of buspirone’s anxiolytic action
33. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis
34. Dangerous potentiation of pethidine by iproniazid, and its treatment
35. Reactions to other drugs in patients taking monoamine-oxidase inhibitors
36. Dangers of monoamine oxidase inhibitors
37. Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride
38. Toxicity secondary to meperidine in patients on monamine oxidase inhibitors: a case report and critical review
39. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid
40. Phenelzine sulfate-dextromethorphan interaction: a case report
41. The serotonin syndrome associated with paroxetine, an over the counter cold remedy, and vascular disease
42. Reactions due to the combination of monoamine oxidase inhibitors with thymoleptics
43. A comparison of the effect of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor
44. Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with a monoamine oxidase inhibitor
45. Potentiation of amphetamine and pethidine by monoamine oxidase inhibitors
46. Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits
47. The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice
48. Role of brain monoamines in the interaction between pethidine and tranylcypromine
49. Central and peripheral monoaminergic membrane pump blockade by some addictive analgesics and antihistamines
50. Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment
51. Monoamine oxidase inhibitors and anaesthesia
52. Interaction of fluoxetine and pentazocine
53. Adverse interaction between propoxyphene and phenelzine
54. The serotonin syndrome in a patient receiving sertraline after an ankle block
55. Central nervous system effects of ingestion of L-tryptophan by normal subjects
56. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor
57. Potentiation of a monamine oxidase inhibitor by tryptophan
58. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan
59. Reduction of the central effects of tryptophan by a decarboxylase inhibitor
60. Case report of a toxic reaction from a combination of tryptophan and phenelzine
61. Myoclonus and ocular oscillations induced by L-tryptophan
62. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment
63. The serotonin syndrome: case responsive to propranolol
64. Serotonin syndrome: a case report
65. Toxic reaction following the combined administration of fluoxetine and L-tryptophan
66. Toxic somatic and psychopathological reactions to antidepressant drugs
67. Possible synergistic effects of the new thymoleptics in connection with poisoning
68. Transient brain syndrome as a nonfatal reaction to combined pargyline-imipramine treatment
69. Toxicity by interaction of tricyclic antidepressant and monoamine oxidase inhibitor
70. Adverse reaction following treatment with monoamine oxidase inhibitors and imipramine and similar drugs: report on two cases — one successfully treated with chlorpromazine
71. Possible development of the serotonin syndrome in man
72. Efficacy and adverse effects of moclobemide
73. Serotonin syndrome
74. Combined MAOI-tricyclic antidepressant treatment: a reevaluation
75. Adverse consequences of fluoxetine-MAOI combination therapy
76. Sertraline and isocarboxazid cause a serotonin syndrome
77. Danger of MAOI therapy after fluoxetine withdrawal
78. Treatment of the serotonin syndrome with cyproheptadine
79. Possible interaction between sertraline and tranylcypromine
80. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome
81. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
82. Possible interactions between Deprenyl and Prozac
83. Interaction of fluoxetine and selegiline
84. Potential fluoxetine-selegiline interaction
85. Serotonin syndrome from trazodone and buspirone
86. 1A selective drugs on the 5-HT behavioral syndrome
87. Serotonin syndrome produced by a combination of fluoxetine and lithium
88. Serotonin syndrome during clomipramine and lithium treatment
89. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome — a possible link?
90. Ecstasy-fueled ‘rave’ parties become dances of death for English youths
91. Multiple severe complications from recreational ingestion of MDMA (ecstasy)
92. Ecstasy, 3-4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia
93. Another death from ecstasy
94. Hyperpyrexia and rhabdomyolysis after MDMA (‘ecstasy’) abuse
95. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’)
96. ‘Eve’ and ‘Ecstasy’: a report of five deaths associated with the use of MDEA and MDMA
97. Possible interaction between an MAOI and ‘ecstasy’
98. A case of MAO inhibitor/MDMA interaction: agony after ecstasy
99. L-dopa induced ‘serotonin syndrome’ in a Parkinsonian patient on bromocriptine
100. The serotonin syndrome
101. Toxic interaction of S-adenosylmethionine and clomipramine
102. Monoamine oxidase inhibitors revisited
103. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression
104. Combined monamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study
105. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients
106. An update of recent moclobemide interaction data
107. Fluoxetine and selegiline — lack of significant interaction
108. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine
109. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan
110. The role of brain dopamine in the hyperactivity syndrome produce by increased 5-HT synthesis in rats
111. An animal behavior model for studying central serotonergic synapses
112. Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake
113. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat
114. 1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di- n-propylamino)tetralin in the rat
115. The pharmacology of the behavioural and hyperthermic responses of rats to 8-hydroxy-2-(di- n-propylamino)tetralin (8-OH-DPAT)
116. 1A receptor in 5-HT syndrome induced in mice by tryptamine
117. Molecular biology of 5-HT receptors
118. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-dopa to rats
119. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake
120. Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxy-amphetamine in MAOI-pretreated rabbits
121. Hyperthermia in psychostimulant overdose
122. 3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol
123. 1A selective agonists
124. (-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system
125. Blockade of 5-hydroxytryptamine receptors in the central nervous system by β-adrenoceptor antagonists
126. New data intensify the agony over ecstasy